Navigation Links
PROLOR Biotech To Present New Preclinical Data On Its Long-Acting Clotting Factor VIIa At Leading European Scientific Conference
Date:2/6/2013

r Haemophilia and Allied Disorders 6th Annual Congress is being held February 6-8, 2013 in Warsaw, Poland.  For more information, visit: http://eahad2013.pl/index.html.

About Hemophilia
Patients with hemophilia do not produce adequate amounts of the clotting factors that are necessary for effective blood clotting.  In severe hemophiliacs even a minor injury can result in blood loss that may continue for days or weeks, with the potential for debilitating permanent damage to joints and other organs and premature death.  According to the World Health Organization, more than 400,000 people worldwide have hemophilia.  Commercially available recombinant clotting factors have enabled many hemophiliacs to live near-normal lives, but frequent injections, infusions and/or blood transfusions may be required. 

About PROLOR
PROLOR Biotech, Inc. is a clinical stage biopharmaceutical company applying unique technologies, including patented CTP technology and its long-acting reversible-pegylation technology, primarily to develop longer-acting proprietary versions of already approved therapeutic proteins that currently generate billions of dollars in annual global sales.  The CTP technology is applicable to virtually all proteins.  PROLOR is developing a long-acting version of human growth hormone, which successfully completed a Phase II clinical trial.  It also is developing long-acting versions of factor VIIa and factor IX for hemophilia and a GLP-1/Glucagon dual receptor agonist peptide for diabetes and obesity, all of which are in preclinical development.  For more information, visit www.prolor-biotech.com.

Safe Harbor Statement:  This press release contains forward-looking statements, which may be identified by words such as "expects," "plans," "projects," "will," "
'/>"/>

SOURCE PROLOR Biotech, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Data From Phase II Trial of Prolor Biotechs Long-acting Human Growth Hormone Presented at Endo 2012
2. PROLOR Biotech Announces Presentation of Data on Its Long-Acting Clotting Factors at World Federation of Hemophilia World Congress
3. PROLOR Biotech To Present Data On Its Long-Acting Human Growth Hormone At International NeuroEndocrine Meeting
4. PROLOR Biotech to Present Data on Its Long-Acting Human Growth Hormone at Pediatric Endocrinology Meeting
5. GenWay Biotech Launches New Cardiovascular Diagnostic Blood Test at American Heart Association Scientific Sessions 2011
6. Puma Biotechnology Announces Completion of Private Placement
7. Animal Biotechnology - Technologies, Markets and Companies
8. AtheroNova and Maxwell Biotech Group Ratify Agreement to Develop New Atherosclerosis Drug
9. The European Union Signs Grant Contract to Fund a 2 Million Euro Biotechnology Research Project Led by Hadassah College Jerusalem
10. Janssen Biotech, Inc. Announces Collaborative Development and Worldwide License Agreement for Investigational Anti-Cancer Drug, PCI-32765
11. Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at CTRC-AACR San Antonio Breast Cancer Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... September 18, 2014 Bipartisan passage this ... bill designed to stimulate development and commercialization of new ... praised by leaders of SPIE, the international society ... American Manufacturing and Innovation (RAMI) Act, now moves to ... have said they are optimistic that it will win ...
(Date:9/18/2014)... LONDON , Sept. 18, 2014 ... near-patient testing, is performed outside a clinical laboratory. ... hence in administrating appropriate treatments and medication. POCT ... and prevalence of lifestyle diseases such as diabetes, ... and user-friendly. POCT devices are standardized to minimize ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 A novel ... an MRI scanner is currently being tested as part ... Women's Hospital in Boston with the aim of determining ... can make prostate cancer biopsies faster, more accurate, less ... system also has the potential to deliver prostate cancer ...
(Date:9/18/2014)... 18, 2014 ... ) has announced the addition of ... Strategic Business Report" report to ... report analyzes the worldwide markets for ... the following Product Segments: Polymeric Materials, ...
Breaking Biology Technology:House passage of high-tech manufacturing bill is move toward stronger economy, say SPIE leaders 2House passage of high-tech manufacturing bill is move toward stronger economy, say SPIE leaders 3POCT Market in China 2014-2018 2Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 2Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 3Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 4Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 5Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 6Biocompatible Materials - Global Strategic Business Report 2014 2Biocompatible Materials - Global Strategic Business Report 2014 3
...  Ambit Biosciences today announced that Michael A. Martino, Ambit,s president ... company and an update about its clinical development programs, including ... in New York City. , 14th Annual BIO ... on Monday, February 13, 2012 , Leerink Swann ...
... 9, 2012  Micross Components, a leading global provider ... to announce its participation in the "Drive for ... Electronics. Included as a "pit stop" during the ... selected because of its role in powering innovation ...
... Inc. (NYSE Amex: CUR ) announces that President ... BIO CEO & Investor Conference 2012 in New York City ... present a business overview, and an update on the company,s ... divisions. (Logo:  http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO ) ...
Cached Biology Technology:Ambit Biosciences to Present at Two Upcoming Investor Conferences 2Micross Components Hosts Stop on "Drive for Innovation" Tour 2Neuralstem President and CEO to Present at BIO CEO & Investor Conference 2012 2Neuralstem President and CEO to Present at BIO CEO & Investor Conference 2012 3
(Date:9/18/2014)... September 18, 2014 New research into the Crimean-Congo ... a severe hemorrhagic disease in humans similar to that ... for CCHFV infection. This discovery has the potential to ... pathogen. , The research, reported in a ... and conducted by scientists at the Texas Biomedical ...
(Date:9/18/2014)... foliage season that prompts millions of Americans to undertake jaunts ... possibly last a little longer within a century, according to ... in some areas of the United States as summer temperatures ... the journal Global Ecology and Biogeography . For instance, ... the state tree of New Hampshire could change color ...
(Date:9/18/2014)... 2014Many Americans across racial and ethnic groups describe ... on their day-to-day life, more so than other ... speech (57% of African-Americans, 49% of non-Hispanic whites, ... asked which disease or ailment is the worst ... among African-Americans followed by AIDS/HIV. Hispanics and ...
Breaking Biology News(10 mins):Research milestone in CCHF virus could help identify new treatments 2Fall foliage season may be later, but longer on warmer Earth 2Fall foliage season may be later, but longer on warmer Earth 3Fall foliage season may be later, but longer on warmer Earth 4Americans rate losing eyesight as having greatest impact on their lives 2Americans rate losing eyesight as having greatest impact on their lives 3
... person or set of identical twins. That makes them ... to international travel. But what happens when the tips ... ridges? It,s not the premise for a ... adermatoglyphia. It,s also known as "Immigration Delay Disease," because ...
... Scientists at the University of Plymouth have shown, for the ... effect on the brain and other parts of the central ... nanoparticles which are widely used as a whitening agent in ... applications being considered for the food industry. They found that ...
... common medicines on elderly people were widely reported earlier in the ... not appear to cause further cognitive impairment in those already suffering ... today by the journal Age and Ageing , Dr Chris ... a number of other universities and the NHS describe how they ...
Cached Biology News:Shake hands with the invisible man 2Reassurance for dementia sufferers on impact of common drugs 2
... Time-resolved microscopy is the ultimate tool for ... structures. Its applications previously have been limited ... microscope optics do not transmit in the ... in fluorescence spectroscopy, introduces a filter-based confocal ...
... G bind specifically to Fc regions of ... G conjugates are commonly used as affinity ... subtypes from serum, hybridoma ascites fluids, tissue ... reagents are also commonly used to capture ...
... quick (10 min) assay can detect H2O2 ... 10-acetyl-3,7-dihydroxyphenoxazine (ADHP). H2O2 oxidizes ADHP in a ... resorufin (excitation at 530-571 nm, emission at ... peroxidase in a one-step, homogeneous, no wash ...
... The Reverse-iT™ One-Step Kit is the ... in RT-PCR. It has been specifically ... The Reverse-iT™ One-Step Kit combines ... and ABgene®s Thermoprime Plus DNA Polymerase ...
Biology Products: